Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252881 | 1.00 | KCNH2 (0.39) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL4585792 | 1.00 | KCNH2 (0.39) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL4585267 | 1.00 | KCNH2 (0.39) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL2256644 | 1.00 | KCNH2 (0.39) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL4584285 | 1.00 | KCNH2 (0.39) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL6439117 | 1.00 | KCNH2 (0.39) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL4584794 | 0.98 | TLR8 (0.38) | KCNH2MAPTTLR8CETPEPHX1 | |
| SCHEMBL2254290 | 0.94 | NPC1 (0.37) | TLR8CETPEPHX1NPC1LMNA | |
| SCHEMBL4584654 | 0.87 | CYP2A6 (0.37) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL3671647 | 0.85 | KCNH2 (0.42) | KCNH2MAPTTLR8LIPGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334391-B2 | Functionalized heteroacenes | XEROX CORPORATION (US) | 2012-12-18 | — | — | US | claimed |
| US-7372071-B2 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20070260069-A1 | Functionalized heteroacenes | XEROX CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070235721-A1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION | 2007-10-11 | — | — | US | claimed |
| EP-1843410-B1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORP (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1843410-A2 | Functionalized heteroacenes and electronic devices generated therefrom | Xerox Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260069-A1 | Functionalized heteroacenes | SOD1, AHR, NR0B2 | KCNH2 1459/4885MAPT 4188/4885TLR8 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.